FDA — authorised 15 June 2005
- Application: NDA021821
- Marketing authorisation holder: PF PRISM CV
- Local brand name: TYGACIL
- Indication: POWDER — INTRAVENOUS
- Status: approved
FDA authorised Tygacil on 15 June 2005
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 15 June 2005; FDA authorised it on 1 December 2016; FDA authorised it on 29 September 2017.
PF PRISM CV holds the US marketing authorisation.